Alnylam Pharmaceuticals (ALNY) Equity Income (2009 - 2012)
Alnylam Pharmaceuticals posted quarterly Equity Income of -$881000.0 for Q4 2012, up 7.65% year-on-year from -$818377.8 in Q1 2012, and up 45.38% on a QoQ basis from -$1.6 million in Q3 2012.
Alnylam Pharmaceuticals (ALNY) has 4 years of Equity Income data on file, last reported at -$881000.0 in Q4 2012.
- For the quarter ending Q4 2012, Equity Income rose 7.65% year-over-year to -$881000.0; the trailing twelve-month figure through Dec 2012 stood at -$4.5 million (down 29.02% YoY), and the FY2012 full-year result was -$4.5 million, down 29.02% from the prior year.
- Equity Income for Q4 2012 stood at -$881000.0, up from -$1.6 million in the prior quarter.
- Across five years, Equity Income topped out at -$467000.0 in Q3 2011 and bottomed at -$3.9 million in Q2 2010.
- The 4-year median for Equity Income is -$1.1 million (2011), against an average of -$1.3 million.
- The widest annual swing landed in 2010, when Equity Income plunged 380.27%; it then jumped 74.18% in 2011.
- A 4-year view of Equity Income shows it stood at -$1.5 million in 2009, then surged by 38.44% to -$916000.0 in 2010, then decreased by 4.15% to -$954000.0 in 2011, then grew by 7.65% to -$881000.0 in 2012.
- The last three Equity Income figures came in at -$881000.0 (Q4 2012), -$1.6 million (Q3 2012), and -$1.1 million (Q2 2012), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 235,807.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Revolution Medicines | 31.20 Bn | 31.20 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | -881,000.00 |
| Sep 30, 2012 | -1.61 Mn |
| Jun 30, 2012 | -1.14 Mn |
| Mar 31, 2012 | -889,000.00 |
| Dec 31, 2011 | -954,000.00 |
| Sep 30, 2011 | -467,000.00 |
| Jun 30, 2011 | -1.01 Mn |
| Mar 31, 2011 | -1.07 Mn |
| Dec 31, 2010 | -916,000.00 |
| Sep 30, 2010 | -1.23 Mn |
| Jun 30, 2010 | -3.92 Mn |
| Mar 31, 2010 | -1.58 Mn |
| Dec 31, 2009 | -1.49 Mn |
| Sep 30, 2009 | -1.14 Mn |
| Jun 30, 2009 | -816,000.00 |